Intrinsiqq
Burzynski Research Institute Inc. logo

Burzynski Research Institute Inc. Financials

BZYR

Compare

All currency values in $ millions unless otherwise noted

Scroll

Showing 6 of 16 available years
Income Statement
TTM
FEB 2025
FEB 2024
FEB 2023
FEB 2022
FEB 2021
Revenues
Revenue$0$0$0$0$0$0
General & Administrative$0$0$0$0$0$0
Research & Development$1$1$1$1$1$1
Total Operating Expenses$1$1$1$1$1$1
Operating Income-$1-$1-$1-$1-$1-$1
EBT (Earnings Before Tax)-$1-$1-$1-$1-$1-$1
Income Tax Expense$0$0$0$0$0$0
Net Income
Net Income-$1-$1-$1-$1-$1-$1
Per Share Data
Revenue Per Share$0.00$0.00$0.00$0.00$0.00$0.00
EPS (Basic)-$0.01-$0.01-$0.01-$0.01-$0.01-$0.01
EPS (Diluted)-$0.01-$0.01-$0.01-$0.01-$0.01-$0.01
Weighted Avg Shares (Basic)131.4M131.4M131.4M131.4M131.4M131.4M
Weighted Avg Shares (Diluted)131.4M131.4M131.4M131.4M131.4M131.4M
Shares Outstanding131.4M131.4M131.4M131.4M131.4M131.4M

Burzynski Research Institute (BZYR) financials: revenue, profit and margins

Burzynski Research Institute (BZYR) generated about $0.00 in revenue and -$1 million in net income over the trailing twelve months. Figures are from SEC filings; this is analysis, not investment advice.

Frequently asked

What is Burzynski Research Institute's (BZYR) revenue?+

Burzynski Research Institute generated about $0.00 in revenue over the trailing twelve months. Revenue is the top line, before any costs; what matters for value is how much of it survives to free cash flow. The full income statement, balance sheet and cash-flow statement are on this tab.

Is Burzynski Research Institute profitable?+

Burzynski Research Institute reported about -$1 million in net loss over the trailing twelve months. Net income is the bottom line after all costs, interest and taxes. Compare it to free cash flow on this tab, since reported profit and actual cash generated can diverge.

How the market compares: How many US companies are profitable

SourceFinancial statements computed from the 10-Q filed 13 Jan 2026, covering the period ending 30 Nov 2025, as reported to the SEC. Data last refreshed 23 Sept 2026. How this is calculated.

Fiscal year ends Feb.

Peers

In Vitro & In Vivo Diagnostic Substances · Pick stocks to compare with BZYR

CompareIntrinsic value
BMRABiomerica Inc.
$1.08-1.82%25
AWHLAspira Women's Health Inc.
No recent price0
ICCCImmuCell Corporation
$10.92-2.24%69
VNRXVolitionRx Limited
$0.16+0.00%30
IMDXInsight Molecular Diagnostics Inc.
$1.96+18.07%25
CDIOCardio Diagnostics Holdings Inc.
$1.60-3.03%30
QDELQuidelOrtho Corporation
$8.32-6.73%0
NTLAIntellia Therapeutics Inc.
$10.00+5.04%25

Spot a number that looks wrong? Check it in BZYR's SEC filings or

Download this analysis as a PDF (Pro)

Data sourced from SEC EDGAR filings and third-party price providers. Scores, valuations, and metrics are algorithmic estimates. This is not investment advice. See our Terms and Methodology.

5 of 5 free stocks used today

Keep analysing BZYR

A free account gives you 10 stocks a day, a watchlist and price alerts.

Already have an account?

Or come back tomorrow. Stocks on your watchlist are always free to view.

MarketsPrivacyTerms© 2026 Intrinsiqq

Not financial advice. Analytical data for research only.

Intrinsiqq is a Netherlands-based company operating in Rotterdam, KvK 73238007.